Lv25
162 积分 2024-04-29 加入
Evaluating the incidence of complications among people with diabetes according to age of onset: Findings from the UK Biobank
6小时前
已完结
Heterogeneity in phenotype, disease progression and drug response in type 2 diabetes
1天前
已完结
Targeting the incretin system in obesity and type 2 diabetes mellitus
3天前
已完结
Beinaglutide for weight management in Chinese individuals with overweight or obesity: A phase 3 randomized controlled clinical study
3天前
已完结
Setmelanotide for the treatment of acquired hypothalamic obesity: a phase 2, open-label, multicentre trial
3天前
已完结
Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial
3天前
已完结
Challenges and opportunities in NASH drug development
3天前
已完结
Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation
3天前
已完结
Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials
4天前
已完结
Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial
7天前
已完结
皖公网安备34019202002308
